VSGN- Finally movin back up - Page 33

anyone know why this one is moving up?

Interesting chart:

http://stockcharts.com/h-sc/ui?s=VSG...6068&listNum=2

User of Ohio talked to Neumann yesterday:

He caught me off guard when he called and I didn't have my list of questions I wanted to ask him, but what he did say (as he's always been saying) that they are still heading towards 2 major milestones, which are ero partner and meeting with FDA as planned in first quarter 2007. He of course could not give a time frame on any events. He was in a very good mood, laughing and joking (It was before martini lunch)and still seemed very confident on progress. He told me to get back to him once I had my questions, which I will e-mail him on monday to have him call me again. The best thing I felt about the call was his confidence, and that seemed high? Back to the waiting game.

VSGN will not be delisted this year...

VSGN has the option to TRANSFER to the Nasdaq Capital Markets. That is not any different from the Gloabal Market where VSGN presently is now. Except the critiria is lower to remain listed. The fact is VSGN will still trade on Nasdaq WHETHER IT BE ON "GLOBAL" OR "CAPITAL".
Oh and when if VSGN decides to transfer to the NASDAQ CAPITAL Market (formerly called Nasdaq Smallcap Market). It will be granted 2 SIX months extentionsions relating to Bid price under $1. That would give VSGN until Feb 2008 to get over $1.

Here are the rules read them.

http://www.nasdaq.com/about/nasdaq_listing_req_fees.pdf...

From Yahoo Board

Watching this board discuss the alternatives for maintaining Nasdaq listing is humorous to say the least.

First, the bashers discussing how bad it’ll be on OTC is ridiculous: under NO circumstances will Vasogen let this stock be delisted from Nasdaq. Nasdaq accounts for almost 90% of the trading volume for this stock and those recent pp institutions are expecting the liquidity of the Nasdaq market. Also once delisted, the hurdle to get relisted is intense including a $5 minimum. Not to mention that if VSGN goes OTC; than Vasogen’s convertible note is immediately callable. Therefore, no matter how many wet dreams the bashers here are having over the idea, VSGN is not going to end up on OTC (BB or pinksheets).

Next, the longs here are also being disingenuous. Discussing how to comply with Nasdaq’s $1 minimum and not mentioning a reverse split; is like talking about sailing across the ocean and not mentioning the boat. IMO a reverse split has been the company’s primary strategy for a couple months now. How can one explain the share dilution over the last three months, and ever hope to achieve a $1 minimum anytime in the future unless the company was assuming an R/S. Right now we have over twice the shares that we had when the Nasdaq 6-month notice was given. At $1 the fully diluted market cap is ~$190M. IMO a reverse split now on the order of 1-for-10 will keep us listed for the long term and gets us to a price that some institutions might be able to buy. Nasdaq Capital Market is only a temporary fix that makes Nasdaq-GM relisting ($5 minimum and ~$1B market cap) almost impossible without an R/S. So, R/S now to stay on; or R/S later to get back.

So as I’ve posted before, this is how I see this developing. On Feb5th plus a day or two, DE will get the notice that VSGN will be delisted unless the company appeals. The company has 7 days to appeal as noted below. IMO that appeal will request a 60-day extension until after the ASM on 4/3 at which time the company is requesting shareholders approve a 1-for-10 RS. The only sticking point is it takes a 2/3 supermajority to approve the R/S. The company might propose that VSGN goes to Capital Market if shareholders do not approve the R/S.

JMHO;

-the bum

------
http://www.nasdaq.com/about/FAQsHearings.stm

When NASDAQ determines to delist a company due to its failure to meet continued listing standards, NASDAQ will send written notice of a determination to delist, which will include the basis for the delisting. The company then has 7 calendar days from the date of the determination letter to request a hearing. A request for a hearing will stay the delisting pending a determination by the Hearing Panel. Failure to request a hearing within 7 calendar days will result in the company's suspension and delisting, pursuant to the terms of the delisting determination. …………
In your submission to the Listing Qualifications Panel, please note the following suggested guidelines:
- Your submission should be definitive, concise, and directly address your company’s plan to regain compliance within the near term and maintain compliance over the long term.
- The plan of compliance should discuss how the company intends to remedy the deficiency within the next 30-60 days and should evidence the company’s ability to sustain such compliance for the next six to twelve months.

Listened to the Conference Call today... They stated they were in the final stages of negotiation with a EU company to bring celacade to market in the EU... They said it could be as early as first half of this year! Also will be filing to meet with FDA very soon to pursue FDA approval for Celacade! They will be moving to NASDAQ Capital Market which will buy them time (6 months) to get the stock price up to $1... When I was listening I could tell they really think they can achieve this with the EU stuff going on... Just thought I would post quickly with some highlights... All good news IMO!!

Has anyone else listened to their conference call from 1-31? From what I heard they already have the green light drug approval to sell celacade in the EU... WHICH IS HUGE!! It seemed like they are just finalizing a partnership with a EU company to manufacture and market it in the EU and then it is off to market we go... can anyone confirm that they heard this as well?

Overall a decent day with a lot of shares trading...

News?

Was anyone in on the conference call? I see the stock is slipping but innovation looks decent. Its close enough to a 52 week low, but it seems to be dropping. I'm considering getting in....

See my posts above concerning the conference call... it was about a half hour long so won't take long to listen to and is well worth it... sounds like EU product launch to market should happen this year! Which is great news! I believe the call should be archived to listen to off of their website... Quote from press release: "A re-broadcast of the conference call may be accessed by calling 416-641-2130 or 1-888-330-1923, pin code 9115#, and will also be available at www.vasogen.com."

Wow... I cannot believe that no one is chatting about this today... It is a rough day across the board in the market and this thing is flying high today... the only new news out to cause this is that Rodman & Renshaw have initiated coverage of VSGN... (is Rodman & Renshaw more important than I realize, or are they just another group??)

So far today over 7 Million shares traded versus 3.7 average day!

This thing will really FLY when they announce their EU partner soon!

Everyone is missing the boat with this stock... nobody knows that they have EU approval (and about their looming announcement of an EU partner for production and marketing) unless they listened to the conference call...

GLTA!!

Lol, you and me both, I figured there would be a 10+ page long thread by now. I noticed volume going crazy this morning so I got in at .40, it's sitting at .45 now and looks like it may reach .50 by eod.

This is on watch today, if we can get through .49-.51 this could really take off imo

Monday, March 12 2007 5:14 AM, GMT-05:00

--------------------------------------------------------------------------------

Filing of Prospectus Supplement Spurs Review: Sector Insight

M2 "Press Wire "

M2 PressWIRE - March 12, 2007 - To read this review in its entirety, please visit www.pinnacledigest.com.

Vasogen Inc. (NASDAQ:VSGN) (TSX:VAS) experienced a loss of 2.08% Friday along with 276,206 shares traded. They recently announced the filing of a prospectus supplement with the Ontario Securities Commission and the U.S. Securities and Exchange Commission (SEC) to increase by 10 million the number of common shares that may be sold by certain selling shareholders in connection with the senior convertible notes issued in October 2005 by Vasogen Ireland Limited (VIL), a wholly-owned subsidiary of Vasogen Inc. PinnacleDigest is reviewing this fact and will be taking a closer look at this company and its operations in the months ahead of us.

As stated in past articles acquisitions and alliances of biotechnology companies have been on the rise of late. This fact becomes very clear when reviewing the figures of last year. Bigger drug makers can foresee a future in which the environment and demand for drugs is a very positive one over the coming 25 years.

At PinnacleDigest we strive to not only bring you an unbiased, informative, broad approach to the industry, but to specifically analyze specific companies in respect to that approach. The first step in this process is to review the company in contrast to the influences within the sector affecting them. To continue with this review in its entirety, come explore our growing online financial magazine at www.pinnacledigest.com.

Rep. Patrick Kennedy is planning to initiate the use of personal health records through a trust fund that pays doctors. The new version of his bill was introduced March 1.

It is known as the Personalized Health Information Act and would require the Department of Health and Human Services to create a public-private PHR incentive program and trust fund to pay physicians. Physicians would be paid up to three years and at least $3 per eligible patient enrolled to use a PHR. We will come back to this issue and its possible long term affects on this company and the healthcare sector.

In respect to Vasogen Inc. they have also very recently announced that Terrance H. Gregg has succeeded David G. Elsley as President and Chief Executive Officer of Vasogen. Mr. Gregg joined Vasogen's Board of Directors in 1999, was appointed Vice Chairman in November 2005, and became Chairman of the Board in March 2006. A change in leadership role of this magnitude needs to be reviewed as it will have a significant influence on this company's future. To continue with Vasogen Inc. and to learn more about our growing online financial magazine as well as corporate developments stemming from this company come explore us at www.pinnacledigest.com.

To continue with this report as well as other related articles, please visit www.pinnacledigest.com for a complimentary membership. It should be stated that our membership requires no commitment to our service. If you would like to contact us please write to support@pinnacledigest.com.

PinnacleDigest has no vested interest in the company mentioned herein. This source of information is from an unbiased perspective. If you wish to become a member of www.pinnacledigest.com you will be gaining access to articles similar to this one and many other useful services we know you will find valuable. Keeping you educated and up-to-date with the market is one of our main purposes. Our approach in achieving this goal and our ability to consistently deliver high quality investment material is what defines our business model.

Investors seeking a distinctive approach to investing should also visit www.pinnacledigest.com for a complimentary membership.

About Pinnacle Digest

Pinnacledigest.com is an emerging online financial newsletter community. We put together informative material, capturing the information that we know will give you an edge to your portfolio and more specifically your investment approach.

Once a member of PinnacleDigest you will be able to access our complimentary full-length research reports on selected companies, our weekly volumes, and our market overviews. In addition to these services we are confident you will enjoy our many other services, as well as our main feature which is available to all our members.

We pride ourselves in having a multi purpose online magazine and encourage you to join our community.

This news release shall not constitute an offer to sell or the solicitation of any offer to buy securities in any jurisdiction.

Anyone still in on this? Im considering selling and cutting my losses...

Technically its trending upwards now. 150MA just crossed the 200MA and if/when it hits the bottom of the channel I'll probably buy some. It looks like it should fall some more though so maybe wait till it bottoms and reverses to average down?

Been tracking this for a while. I guess this was their only option to maintain their NASDAQ listing.